Drug Repurposing in LGSOC: Faster Access to Life-Saving Treatments

Drug repurposing is finding new uses for medications already approved by the FDA for other diseases. And it  is changing how we treat low-grade serous ovarian cancer (LGSOC).

Instead of waiting over a decade for brand-new drugs to complete development, researchers are borrowing proven medications from breast cancer, melanoma, and other diseases.

Why does this work? Because LGSOC shares the same biological pathways that drive these other cancers. It’s like discovering that the key to your neighbor’s house also unlocks yours: same mechanism, different door.

The impact goes beyond faster timelines. These borrowed drugs are often more effective than standard chemotherapy for LGSOC. And because they’ve already been used safely in thousands of patients, we understand their side effects and how to manage them.

Why Low-Grade Serous Ovarian Cancer Needs Different Treatment

Here’s the fundamental problem: LGSOC isn’t just a milder version of high-grade serous ovarian cancer. It’s biologically different, and that difference matters when it comes to treatment.

Think about how chemotherapy works. These drugs are designed to kill rapidly dividing cells: cells that are constantly splitting and multiplying. That’s why chemo causes hair loss: hair follicle cells divide quickly and are collateral damage. 

Nausea works differently. Chemo triggers specialized cells in the GI tract called enterochromaffin cells to release serotonin, which signals nearby nerves, which then signal the brain’s vomiting center. The same principle — that chemo targets rapidly dividing cells — should apply to cancer cells.

But LGSOC tumors don’t divide quickly. They grow slowly and steadily. It’s like trying to catch a speeding car with a speed trap: if the car isn’t speeding, the trap won’t work.

Put simply: Low-grade grows much more slowly than high-grade and has completely different mutations driving the disease. Using the same platinum-based chemotherapy protocols that work for high-grade simply doesn’t make sense for low-grade patients.

The chemotherapy that works brilliantly for high-grade ovarian cancer often fails in LGSOC. Not because doctors are doing something wrong, but because the biology is different.

That’s precisely why drug repurposing offers such promise. Instead of trying to force chemotherapy to work, researchers are using drugs that target what actually drives LGSOC growth.

What Is Drug Repurposing?

Drug repurposing (also called drug repositioning or drugs being prescribed for “off-label” use) means taking an FDA-approved medication designed for one disease and using it to treat a different condition.

The classic example? Viagra. Originally developed to treat heart conditions, researchers discovered it had a very different effect. Instead of abandoning the drug, they repurposed it.

In cancer treatment, drug repurposing works because many cancers share the same underlying biology: the same faulty switches, the same broken pathways, the same growth signals gone wrong.

Why this approach is faster: Traditional drug development takes over a decade. Scientists have to discover a compound, test it in labs, prove it’s safe in animals, then move through multiple phases of human trials. Each step takes years.

With drug repurposing, much of that work is already done. The drug is already FDA-approved for something else. We already know it’s safe. We understand how the body processes it. We know what side effects to expect.

This means we can skip straight to testing whether it works for a new condition. What would normally take 10 to 15 years can happen in 3 to 12 years.

Why this matters for rare cancers: LGSOC represents only a small fraction of ovarian cancers. Pharmaceutical companies have limited financial incentive to develop brand-new drugs for such a small patient population.

But repurposing is different: The drug already exists and the infrastructure to manufacture it is already in place. It’s just being used in a new way.  

Why Repurpose Drugs for Cancer? The Shared Biology

The secret lies in understanding what makes cancer cells grow in the first place.

Cancer is caused by specific malfunctions in the body’s normal systems. Different cancers can have the same faulty parts, even if they start in completely different organs. LGSOC shares these faulty parts with two other cancers: breast cancer and melanoma.

The hormone connection with breast cancer: Most LGSOC tumors depend on estrogen to grow. Estrogen acts like fertilizer for these cancer cells: the more estrogen available, the more the tumor can grow.

This is exactly the same biology we see in hormone-positive breast cancer. For decades, doctors have successfully treated breast cancer by blocking estrogen. Drugs like aromatase inhibitors (letrozole, anastrozole) essentially starve the tumor by cutting off its estrogen supply.

If these drugs work by blocking estrogen in breast cancer, and LGSOC tumors also depend on estrogen, then logically these same drugs should work in LGSOC as well. 

The MAPK pathway connection with melanoma: Inside every cell are signaling pathways. Think of these as communication networks that tell the cell when to grow, when to divide, when to die. One of these networks is called the MAPK pathway.

In LGSOC, this pathway is broken. Mutations in genes like KRAS, BRAF, and NRAS cause the pathway to send constant “grow and divide” signals, even when the cell shouldn’t be growing. It’s like a stuck gas pedal in a car. Melanoma has the exact same problem: the exact same stuck gas pedal, caused by mutations in the exact same genes.

Drugs called MEK inhibitors fix this problem by jamming the pedal and blocking the faulty signals in the MAPK pathway, stopping the “grow and divide” message from getting through. These drugs were originally developed for melanoma, but are being repurposed for LGSOC patients who have the same faulty pathway.

The bottomline: Drug repurposing works because cancer biology is often shared across different tumor types. By understanding these connections, researchers can borrow effective treatments from one cancer and adapt them for another.

Repurposed Drugs for LGSOC

Several repurposed drugs have moved from promising theory to proven results in clinical trials.

Aromatase Inhibitors: Borrowed from Breast Cancer

How they work: Even after your ovaries are removed during cancer surgery, your body still produces estrogen. How? Fat tissue contains an enzyme called aromatase that converts other hormones into estrogen.

Aromatase inhibitors block this enzyme. No enzyme activity means no estrogen conversion. And without estrogen, tumors that depend on it for growth essentially starve.

Why they matter for LGSOC: Anastrozole and letrozole are two aromatase inhibitors that have been successfully repurposed from breast cancer treatment to LGSOC. Both have shown real benefits in clinical trials, helping to keep cancer stable or even shrink tumors in many patients.

These aren’t experimental drugs with unknown risks. Aromatase inhibitors have been used safely in millions of breast cancer patients for decades. The side effects — hot flashes, joint pain, bone density changes — are well understood.

MEK Inhibitors: Borrowed from Melanoma

How they work: MEK is an enzyme in the MAPK pathway, that faulty communication network we talked about earlier. When MAPK mutations cause constant “grow and divide” signals, MEK acts as the messenger carrying those signals through the cell.

MEK inhibitors block this messenger. By stopping MEK from functioning, these drugs interrupt the growth signals before they reach the cell’s nucleus. The message to “grow and divide” never gets delivered, and tumor growth slows or stops.

Why they matter for LGSOC: A clinical trial compared trametinib (a MEK inhibitor originally approved for melanoma) to standard chemotherapy in women with recurrent LGSOC. The results were compelling enough that MEK inhibitors are now included in national treatment guidelines as an option for recurrent LGSOC.

The side effects of MEK inhibitors — skin rash, diarrhea, fatigue — are generally manageable and well-understood from years of use in melanoma patients.

CDK4/6 Inhibitors: Another Breast Cancer Success

How they work: Cells have checkpoints: built-in safety systems that control when a cell is allowed to divide. CDK4 and CDK6 are proteins that act like security guards at these checkpoints, deciding whether to let the cell proceed with division or not.

In cancer, these security guards often malfunction, waving cells through the checkpoint even when they shouldn’t divide. CDK4/6 inhibitors essentially replace the faulty guards with competent ones who actually do their job, stopping cells from dividing inappropriately.

Like aromatase inhibitors and MEK inhibitors, CDK4/6 inhibitors have an established track record in breast cancer. When you combine CDK4/6 inhibitors with hormone therapy, you’re attacking the cancer on two fronts: cutting off the estrogen that fuels growth while also preventing the cells from dividing.

Why they matter for LGSOC: Recent clinical trials have tested this combination approach, pairing a CDK4/6 inhibitor (ribociclib) with an aromatase inhibitor (letrozole). The results showed that most patients experienced either tumor shrinkage or stable disease, with many responding for well over a year.

Understanding Why These Drugs Work: The Biology Explained Simply

You don’t need a biology degree to understand why drug repurposing works in LGSOC. It comes down to three key biological features:

LGSOC tumors depend on estrogen

Just like some breast cancers need estrogen to grow, so do most LGSOC tumors. They have receptors on their surface that grab onto estrogen molecules floating by. When estrogen binds to these receptors, it’s like putting gas in a car: the tumor has fuel to grow.

Block the estrogen, and you starve the tumor. That’s exactly what aromatase inhibitors and other hormone therapies do.

LGSOC has a broken growth pathway

The MAPK pathway is one of several communication networks inside cells that controls growth. In LGSOC, mutations in genes like KRAS, BRAF, and NRAS break this pathway so it constantly sends “grow” signals, even when the cell should be resting.

Melanoma has the exact same problem. That’s why MEK inhibitors developed for melanoma also work in LGSOC — they fix the same broken pathway.

LGSOC has faulty cell division checkpoints

Normal cells have safety systems that prevent uncontrolled division. One of these systems involves CDKN2A, a gene that helps regulate proteins called CDK4 and CDK6.

In some LGSOC tumors, CDKN2A is mutated, so CDK4 and CDK6 run wild, allowing cells to divide unchecked. CDK4/6 inhibitors step in and do the job that CDKN2A was supposed to do, keeping cell division under control.

LGSOC isn’t driven by one single problem. Different tumors have different combinations of these biological issues. That’s why molecular testing is so important. It reveals which specific problems your tumor has, which helps doctors choose the most effective repurposed drugs.

How Repurposed Drugs Reach Patients

Even with all the advantages of drug repurposing, these treatments don’t become available overnight. Understanding the process helps explain why some drugs are available now while others are still in clinical trials.

The traditional FDA pathway: New cancer drugs typically go through a structured approval process:

• Laboratory testing: Scientists study how the drug works in cells and animals
• Phase 1 trials: Small studies to identify the highest dose patients can safely tolerate
• Phase 2 trials: Larger studies to find the optimal dose that balances effectiveness with tolerability
• Phase 3 trials: Large randomized trials comparing the new drug to the current standard treatment

This process normally takes over a decade. Each phase requires years of patient enrollment, treatment, and follow-up.

The challenge for LGSOC: LGSOC creates unique obstacles:

• It’s rare, making it hard to enroll enough patients in trials
• It grows slowly, so it takes longer to see if treatment is working
• There’s limited pharmaceutical industry investment in rare cancers

The faster pathway: Here’s where it gets interesting — drugs don’t always need full FDA approval specifically for LGSOC to be prescribed.

After successful Phase 2 studies, effective drugs can be added to recognized medical compendia: curated lists of treatments that Medicare and insurance companies will cover, even without formal FDA approval for that specific use. Medicare recognizes several of these compendia, including the NCCN Drugs and Biologics Compendium, the American Hospital Formulary Service Drug Information (AHFS-DI), Micromedex DrugDex, Clinical Pharmacology, and Lexi-Drugs.

This happened with MEK inhibitors. After Phase 2 studies showed they worked, doctors could prescribe them for LGSOC years before the Phase 3 trial was even completed.

There’s also another avenue worth knowing about. Medicare will reimburse off-label chemotherapy use supported by evidence published in 26 designated peer-reviewed journals. 

This matters practically: if a patient is denied coverage based on a lower-evidence recommendation, supporting literature from those journals can be used to appeal the decision. One study found that 87% of such off-label indications had at least one qualifying publication in those journals.

This pathway gets effective treatments to patients years faster than waiting for traditional FDA approval.

What This Means If You Have LGSOC

If you’ve been diagnosed with LGSOC, drug repurposing gives you options beyond chemotherapy.

After surgery and initial treatment, several repurposed drugs are available: aromatase inhibitors for maintenance therapy, MEK inhibitors when cancer returns, and CDK4/6 inhibitors combined with hormone therapy.

Molecular testing matters. Not all LGSOC tumors are identical. Understanding your tumor’s specific mutations — like BRAF or KRAS mutations — helps your doctor choose which repurposed drugs are most likely to work. Ask your oncologist about comprehensive genomic testing.

Clinical trials offer early access. Trials testing novel drug combinations often provide the fastest route to cutting-edge treatments. Search for LGSOC trials at ClinicalTrials.gov or ask your gynecologic oncologist about studies at major cancer centers.

Moving Forward with Realistic Hope

Drug repurposing isn’t a magic cure. These treatments control disease rather than eliminate it. Cancer can develop resistance. And treatment timelines still require patience; even fast-tracked drugs take years to reach patients.

But the landscape has fundamentally changed. A decade ago, women with LGSOC had almost no options beyond surgery and chemotherapy that didn’t work very well. Today, there are multiple repurposed drugs available, with more in clinical trials. These treatments target the actual biology driving LGSOC growth, not just generic cancer cell division.

Drug repurposing has given us a roadmap, taking what works in breast cancer and melanoma and adapting it for LGSOC. That roadmap is already helping patients live longer with better quality of life.